Mundipharma wins contract to launch Kolon's Invossa in Japan

Mundipharma won an exclusive technology export contract from Kolon Life Science to launch Invossa, a cell-mediated gene therapy for degenerative arthritis, in Japan. The contract is effective for 15 years after launch, with a total value of $591.6 million.

“Mundipharma has exclusive rights to research, develop, patent and commercialize Invossa in Japan.”ajupress.com

• 1 source
• ajupress.comU.S. company Mundipharma wins contract to launch Kolon's Invossa in Japan | Aju PressLim Chang-wonNov 19, 2018

Summarized from public sources; check the original articles before acting on it.